CXCR4 Antibody (monoclonal) (M04)
Mouse monoclonal antibody raised against a partial recombinant CXCR4.
- CITATIONS: 1
|Application ||WB, E|
|Calculated MW||39746 Da|
|Other Names||C-X-C chemokine receptor type 4, CXC-R4, CXCR-4, FB22, Fusin, HM89, LCR1, Leukocyte-derived seven transmembrane domain receptor, LESTR, Lipopolysaccharide-associated protein 3, LAP-3, LPS-associated protein 3, NPYRL, Stromal cell-derived factor 1 receptor, SDF-1 receptor, CD184, CXCR4|
|Target/Specificity||CXCR4 (AAH20968, 1 a.a. ~ 46 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.|
|Format||Clear, colorless solution in phosphate buffered saline, pH 7.2 .|
|Storage||Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing.|
|Precautions||CXCR4 Antibody (monoclonal) (M04) is for research use only and not for use in diagnostic or therapeutic procedures.|
Provided below are standard protocols that you may find useful for product applications.
This gene encodes a CXC chemokine receptor specific for stromal cell-derived factor-1. The protein has 7 transmembrane regions and is located on the cell surface. It acts with the CD4 protein to support HIV entry into cells and is also highly expressed in breast cancer cells. Mutations in this gene have been associated with WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome. Alternate transcriptional splice variants, encoding different isoforms, have been characterized.
CXCR4/YY1 inhibition impairs VEGF network and angiogenesis during malignancy. de Nigris F, et al. Proc Natl Acad Sci U S A, 2010 Aug 10. PMID 20660740.CXCR4, a potential predictive marker for docetaxel sensitivity in gastric cancer. Xie L, et al. Anticancer Res, 2010 Jun. PMID 20651371.Decreased interstitial FOXP3(+) lymphocytes in usual interstitial pneumonia with discrepancy of CXCL12/CXCR4 axis. Shimizu Y, et al. Int J Immunopathol Pharmacol, 2010 Apr-Jun. PMID 20646340.Variation at the NFATC2 Locus Increases the Risk of Thiazolinedinedione-Induced Edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) Study. Bailey SD, et al. Diabetes Care, 2010 Jul 13. PMID 20628086.Differences in donor CXCR4 expression levels are correlated with functional capacity and therapeutic outcome of angiogenic treatment with endothelial colony forming cells. Oh BJ, et al. Biochem Biophys Res Commun, 2010 Aug 6. PMID 20599766.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.